2021
DOI: 10.1590/0102-672020210001e1574
|View full text |Cite
|
Sign up to set email alerts
|

Cytoplasmic-Membrane Egfr Predicts Expanded Ras Mutation Status in Colorectal Carcinomas?

Abstract: Background: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the EGFR by immunohistochemistry predicting the mutation status of the expanded RAS (KRAS and NRAS), may allow treatment by a diagnostic method less costly and more accessible. Aim: Investigate the correlation between t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 27 publications
(46 reference statements)
0
1
0
Order By: Relevance
“…However, the final conclusion of this research is that the diagnosis practically does not change 19 . Other publications report that immunohistochemistry still needs to be improved for serrated lesions 3 , 6 , 14 , 24 , as well as the use of molecular investigations 3 , 23 , 24 .…”
Section: Discussionmentioning
confidence: 99%
“…However, the final conclusion of this research is that the diagnosis practically does not change 19 . Other publications report that immunohistochemistry still needs to be improved for serrated lesions 3 , 6 , 14 , 24 , as well as the use of molecular investigations 3 , 23 , 24 .…”
Section: Discussionmentioning
confidence: 99%